Bio-Technology General Corp. to Announce Third Quarter 2002 Earnings Results and Host Live Webcast Discussion On November 14, 2002.

Business Editors & Health/Medical Writers

BIOWIRE2K

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Nov. 12, 2002

Bio-Technology General Corp. (Nasdaq:BTGC) will announce its third quarter 2002 earnings results on Thursday, November 14, 2002, prior to the market opening.

The announcement will be followed by a live webcast discussion of the earnings and the Company's business for the quarter, hosted by Sim Fass, Chairman and CEO, at 10:30 a.m. ET. The webcast can be accessed at www.btgc.com, BTG's web site, and will be archived through November 21, 2002.

An audio replay will also be available from November 14, 2002 after 12:30 p.m. ET through November 21, 2002 and can be accessed by dialing 800/428-6051 (in the U.S.) or 973/709-2089 (outside the U.S.); passcode number is 268577.

Bio-Technology General Corp. develops, manufactures and markets genetically engineered and other products for human health care. BTG's products are marketed worldwide. Products sold in the United States are Oxandrin(R) (oxandrolone, USP), marketed by BTG and by the Ross Products Division of Abbott Laboratories under a co-marketing agreement; Delatestryl(R) (testosterone enanthate), marketed by BTG; Mircette(R) (oral contraceptive), marketed by Organon Inc.; and BioLon(TM) (sodium hyaluronate), marketed by Akorn Inc.

Products sold internationally are Bio-Tropin(TM) (recombinant human growth hormone); BioLon(TM) (sodium hyaluronate); Bio-Hep-B(TM) (hepatitis B vaccine); Silkis(R) (vitamin D derivative); Arthrease(TM) (sodium hyaluronate for osteoarthritis); and recombinant human insulin. BTG's news releases and other information are available on the Company's web site at www.btgc.com.

Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission.

Note to Editors: Arthrease is a trademark of DePuy Orthopaedics, Inc.; Mircette is a registered trademark of Organon Inc.; Silkis is a registered trademark of Galderma.